Prelude Therapeutics (PRLD)
(Delayed Data from NSDQ)
$3.87 USD
0.00 (0.00%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $3.88 +0.01 (0.26%) 7:08 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Detailed Estimates
EPS Estimates
Exp Earnings Date | 5/13/24 |
---|---|
Current Quarter | -0.47 |
EPS Last Quarter | -0.47 |
Last EPS Surprise | 6.00% |
ABR | 2.34 |
Earnings ESP
|
0.00% |
---|---|
Current Year | -1.88 |
Next Year | -1.74 |
EPS (TTM) | -2.04 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | NA | NA | NA | NA |
# of Estimates | NA | NA | NA | NA |
High Estimate | NA | NA | NA | NA |
Low Estimate | NA | NA | NA | NA |
Year ago Sales | 0.00M | 0.00M | NA | NA |
Year over Year Growth Est. | NA | NA | NA | NA |
Earnings Estimates
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -0.47 | -0.47 | -1.88 | -1.74 |
# of Estimates | 2 | 2 | 3 | 1 |
Most Recent Consensus | -0.44 | -0.45 | -1.83 | NA |
High Estimate | -0.44 | -0.45 | -1.83 | -1.74 |
Low Estimate | -0.49 | -0.49 | -1.96 | -1.74 |
Year ago EPS | -0.58 | -0.54 | -2.02 | -1.88 |
Year over Year Growth Est. | 18.97% | 12.96% | 6.93% | 7.45% |
Agreement - Estimate Revisions
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 0 |
Up Last 30 Days | 0 | 0 | 0 | 0 |
Up Last 60 Days | 0 | 0 | 0 | 0 |
Down Last 7 Days | 0 | 0 | 0 | 0 |
Down Last 30 Days | 0 | 0 | 0 | 0 |
Down Last 60 Days | 0 | 0 | 0 | 0 |
Magnitude - Consensus Estimate Trend
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Current | -0.47 | -0.47 | -1.88 | -1.74 |
7 Days Ago | -0.47 | -0.47 | -1.88 | -1.74 |
30 Days Ago | -0.47 | -0.47 | -1.88 | -1.74 |
60 Days Ago | -0.47 | -0.47 | -1.88 | -1.74 |
90 Days Ago | -0.49 | -0.51 | -1.86 | -1.52 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | -0.47 | -0.47 | -1.88 | -1.74 |
Zacks Consensus Estimate | -0.47 | -0.47 | -1.88 | -1.74 |
Earnings ESP | 0.00% | 0.00% | 0.00% | 0.00% |
Surprise - Reported Earnings History
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Quarter Ending (6/2023) |
Quarter Ending (3/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | -0.47 | -0.45 | -0.54 | -0.58 | NA |
Estimate | -0.50 | -0.58 | -0.65 | -0.68 | NA |
Difference | 0.03 | 0.13 | 0.11 | 0.10 | 0.09 |
Surprise | 6.00% | 22.41% | 16.92% | 14.71% | 15.01% |
Quarterly Estimates By Analyst
Zacks Premium Subscription Required Learn more
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more